HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese
HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese
复制标题
HLA-B*58:01 等位基因与汉族人别嘌呤醇引起的轻度和重度皮肤不良反应的风险增加相关。
DOI：
10.2217/pgs.12.89
复制
发表时间：
2012-07-01
期刊：
影响因子：
2.1
通讯作者：
Luo, Xiao-qun
中科院分区：
文献类型：
--
作者：
Cao, Zhi Hao;Wei, Zhi-yun;Luo, Xiao-qun
目的
别嘌呤醇作为一种有效的降尿酸药物被广泛使用，是皮肤药物不良反应（cADR）的最常见原因之一。最近，HLA-B*58：01与别嘌呤醇诱导的重度cADR密切相关。本研究调查了中国大陆汉族人群中HLA-B*5801赋予的不同类型别嘌呤醇cADR的易感性。
患者和方法
对2008年至2011年发生不同类型别嘌呤醇cADR的38例中国患者进行HLA-B基因分型。
结果
所有别嘌呤醇-cADR患者均携带HLA-B*58：01，而别嘌呤醇耐受患者中仅11.11%（7/63）（比值比[OR] = 580.07; p < 0.0001）和来自人类MHC数据库的汉族人群中13.99%（80/572）（dbMHC; OR：471.09; p < 0.0001）携带该基因型。每种别嘌呤醇cADR均与HLA-B*58：01存在统计学显著相关性。特别是，HLA-B*58：01患者发生别嘌呤醇诱导斑丘疹的风险显著更高（OR：339.00; p < 0.0001）。
结论
观察到轻度和重度别嘌呤醇cADR与HLA-B*58：01等位基因的强相关性。结果表明，HLA-B*58：01基因检测的前瞻性使用可能会降低别嘌呤醇诱导的cADR的患病率。原件于2012年3月7日提交;修订版于2012年5月21日提交。
AIM
Allopurinol is widely used as an effective urate-lowering drug and is one of the most frequent causes of cutaneous adverse drug reactions (cADRs). Recently, a strong association of HLA-B*58:01 with allopurinol-induced severe cADRs was identified. This study investigated the predisposition to different types of allopurinol-cADRs conferred by HLA-B*5801 in a Han population from mainland China.
PATIENTS & METHODS
HLA-B genotyping was performed on 38 Chinese patients with different types of allopurinol-cADRs from 2008 to 2011.
RESULTS
All the allopurinol-cADR patients carried HLA-B*58:01, in contrast with only 11.11% (7/63) in the allopurinol-tolerant patients (odds ratio [OR] = 580.07; p < 0.0001) and 13.99% (80/572) in a Han Chinese population from the human MHC database (dbMHC; OR: 471.09; p < 0.0001) carried the genotype. Each type of allopurinol cADRs revealed a statistically significant association with HLA-B*58:01. In particular, the risk of allopurinol-induced maculopapular eruption was significantly higher in patients with HLA-B*58:01 (OR: 339.00; p < 0.0001).
CONCLUSION
The strong association of both the mild and severe types of allopurinol cADRs with the HLA-B*58:01 allele were observed. The results indicated that the prospective use of a genetic test of HLA-B*58:01 might reduce the prevalence of allopurinol-induced cADRs. Original submitted 7 March 2012; Revision submitted 21 May 2012.